Skip to main content
LB PHARMACEUTICALS INC logo

LB PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LBRX ISIN · US50180M1080 US Manufacturing
Open in API
Filings indexed 92 across all filing types
Latest filing 2026-06-10 Board/Management Inform…
Country US United States of America
Listing US LBRX

About LB PHARMACEUTICALS INC

https://lbpharma.us/

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric diseases, with a primary emphasis on schizophrenia and bipolar depression. The company's pipeline is centered on its lead product candidate, LB-102, an oral small molecule. LB-102 is being developed as a potential first-in-class benzamide antipsychotic for approval in the United States. The company is advancing LB-102 through late-stage clinical development, including a Phase III trial for schizophrenia and a Phase II study for bipolar depression, to address significant unmet needs in mental healthcare.

Recent filings

Filing Released Lang Actions
424B3
Board/Management Information Classification · 92% confidence The document is a SEC Form 8-K “Current Report” filed under Item 5.02 regarding the departure of the Chief Medical Officer and related separation and consulting agreement. This is an announcement of a senior management change, fitting the Board/Management Information category.
2026-06-10 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed under Item 5.02 detailing the resignation of the Chief Medical Officer and her transition to an advisory role, along with the terms of her separation and consulting agreement. This is an announcement of changes in senior management. Accordingly, it falls under Board/Management Information.
2026-06-10 English
424B3
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a Current Report on Form 8-K filed under Item 5.07 “Submission of Matters to a Vote of Security Holders.” It provides the final voting results from the 2026 Annual Meeting of Stockholders, including tallies for director elections and ratification of the auditor. This constitutes an official declaration of voting results, matching the DVA category.
2026-06-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a Form 8-K reporting item 5.07: Submission of Matters to a Vote of Security Holders, detailing final voting results for the election of directors and appointment of the independent registered public accounting firm at the 2026 Annual Meeting. This corresponds precisely to Declaration of Voting Results & Voting Rights Announcements.
2026-06-09 English
424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
Interim / Quarterly Report Classification · 90% confidence The document is a Form 424B3 prospectus supplement that incorporates and reprints the full quarterly report on Form 10-Q for the period ended March 31, 2026. The text includes condensed balance sheets, statements of operations, MD&A, risk factors and other unaudited quarterly financial statements, which meet the definition of an interim/quarterly report. Therefore, it should be classified as IR (Interim / Quarterly Report). Q1 2026
2026-05-12 English
10-Q - LB PHARMACEUTICALS INC (0001691082) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.